Tenax Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 7.71 million compared to USD 11.05 million a year ago. Basic loss per share from continuing operations was USD 31.04 compared to USD 600.71 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.9 USD | +6.27% | +11.43% | -82.25% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-82.25% | 7.64M | |
+0.17% | 42.19B | |
+10.92% | 42.24B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.23% | 24.63B | |
-24.79% | 18.2B | |
+26.69% | 12.01B | |
-3.13% | 11.76B | |
+6.57% | 10.4B |
- Stock Market
- Equities
- TENX Stock
- News Tenax Therapeutics, Inc.
- Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023